Clinical Trial of Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient Adults

PHASE3SuspendedINTERVENTIONAL
Enrollment

314

Participants

Timeline

Start Date

December 12, 2019

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Influenza
Interventions
DRUG

MMH-407

MMH-407: For oral use.

DRUG

Placebo

Placebo: For oral use.

Trial Locations (20)

117593

Central Clinical Hospital of the Russian Academy of Sciences, Moscow

170100

Tver State Medical University, Department of Hospital Therapy, Tver'

191180

Vvedensky City Clinical Hospital, Saint Petersburg

193312

City Polyclinic # 25 of the Nevsky District, Saint Petersburg

194354

"Medical Center Reavita Med SPb", Saint Petersburg

194356

"Llc Medical Clinic", Saint Petersburg

198207

City Polyclinic # 43, Saint Petersburg

308015

Belgorod State National Research University, Hospital Therapy Department, Belgorod

350063

Kuban State Medical University, Infectious Diseases and Phthisiopulmonology Department, Krasnodar

355000

Scientific Medical Center for General Therapy and Pharmacology, Stavropol

400131

Volgograd State Medical University, Volgograd

420012

Kazan State Medical University, Internal Medicine Department, Kazan'

426063

City Clinical Hospital # 9 of the Ministry of Health of the Udmurt Republic, Izhevsk

443056

Samara City Hospital # 4, Samara

450008

Bashkir State Medical University, Internal Medicine Department, Ufa

454000

Road Clinical Hospital at Chelyabinsk station of JSC Russian Railways, Chelyabinsk

603011

City Clinical Hospital # 10 of the Kanavinsky District of Nizhny Novgorod, Nizhny Novgorod

603140

Road Clinical Hospital at the station Nizhny Novgorod of JSC Russian Railways, Nizhny Novgorod

656038

Altai State Medical University, Department of Faculty Therapy with a course of immunology and allergology, Barnaul

656045

City Hospital # 5, Barnaul

Sponsors
All Listed Sponsors
lead

Materia Medica Holding

INDUSTRY

NCT04250311 - Clinical Trial of Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient Adults | Biotech Hunter | Biotech Hunter